ALFA Finder
18:47 IST
NSE
Results Update
Strides Pharma Science Results Update
Strides Pharma reported Q2FY27 revenue of ₹14,297m, up 17.1% YoY, and EBITDA of ₹2,509m, up 8.4%, in a press release. Reported PAT rose 2.0% to ₹1,341m.
Strides Pharma Science Ltd
- Share price
- ₹999.40
- Market cap
- ₹9,212 Cr
- Revenue (annual)
- ₹4,859 Cr
- Net profit (annual)
- ₹556.2 Cr
- P/E (TTM)
- 14.9×Sector 43.8×
- Promoter holding
- 29.00%+1.09% QoQ
- FII holding
- 27.98%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Earnings Call 6Financial Results 5Merger & Restructuring 4Business Update 4Results Update 3Other Announcement 3Board Meeting Date 3Management Change 2Dividend 2Annual General Meeting 2Employee Stock Options 1Board Meeting Outcome 1
Time
3 announcements with these filters
12:39 IST
NSE
Results Update
Strides Pharma Science Results Update
Strides Pharma Science reported a 13% YoY revenue growth to ₹1,265.4 Crore for Q1FY27. EBITDA grew 5.4% to ₹229.8 Crore despite geopolitical cost disruptions.
- Value
- ₹1,265 Cr
14:27 IST
BSE
Results Update
Strides Pharma Science Results Update
Strides reported strong FY26 performance with EBITDA reaching ₹9,253 million. The Board recommended a dividend of ₹5 per share, reflecting robust growth in Ex-US markets.